Pipeline

Chronic Hepatitis B

Hepatitis B is a condition caused by the hepatitis B virus (HBV). The virus can cause both acute and chronic disease. Chronic hepatitis B (CHB) is a major public health problem. WHO estimates that 254 million people were living with chronic hepatitis B infection, with 1.2 million new infections each year and 1.1 million deaths, mostly from cirrhosis and hepatocellular carcinoma (WHO 2024). Antiviral therapy is effective in controlling the disease but does typically not allow to cure the infection. Hence life-long antiviral therapy is required.

AstriVax Therapeutics´ approach to functional CHB cure

AstriVax Therapeutics is developing  AVX70371, a candidate CHB immunotherapy, that efficiently induces specific CD4+ and CD8+ T-cells and is expected to be a promising component in of a combination therapy that may lead to a functional cure.

Development status: Preclinical PoC, preparing for Phase 1.

Human papillomavirus

Persistent human papillomavirus (HPV) infection is a primary cause of precancerous cervical lesions, which can progress to cervical cancer. Virtually all cervical cancer cases are attributed to HPV.
Despite the availability of effective vaccines for over a decade, around 4% of individuals still carry high-risk HPV types 16 and 18, which are strongly associated with cervical as well as head and neck cancers. The development of therapeutic vaccines for HPV could significantly improve current treatment strategies. These vaccines could simplify treatment, reduce loss-to-follow-up, and increase the proportion of women effectively treated after a positive test result (WHO).

Investigational HPV immunotherapy (AVX70561)

AstriVax Therapeutics is developing an investigational immunotherapy designed to elicit CD8+ T-cells response, aiming to clear persistent infectious and thereby prevent progression to and eliminate pre cancerous lesions.

Development status: Discovery stage

Yellow fever (YF) 

YF is caused by the transmission of the YF virus via the bite of an infected mosquito. It is a highly pathogenic virus with a case fatality rate of more than 30%. There are >30 000 deaths/year with increasing number of cases (CDC). Climate change is expanding the range of mosquito-borne diseases, posing a risk to half of the world’s population. YF vaccination is required for travelers to certain countries and is recommended for all travelers to areas subject to endemic and epidemic disease (WHO). The current surge in market demand is evident​ due to expansion of  travel market​ and new areas of risks.

AstriVax Therapeutics response to increasing need of new generation YF vaccines

AstriVax Therapeutics is providing fast-track validation and proof-of-concept for its proprietary Launch-IT technology by testing AVX70120, the yellow fever based viral vector. Using biomarker data (Correlates of Protection), this initiative aims to demonstrate the platform’s efficacy, scalability, and potential for broader applications.

Development status: Ongoing Phase I clinical study (SAFYR) testing the safety and Immune response of AVX70120

Rabies

Rabies is a preventable viral disease most often transmitted through the bite or scratch of a rabid animal. While rabies is a preventable disease (through pre-exposure prophylaxis and/or post-exposure prophylaxis), an estimated >60 000 people die annually from the disease around the world (CDC) as Rabies is causing acute encephalitis, and it is 100% fatal zoonotic disease.

AstriVax Therapeutics is pioneering a next-gen life saving Rabies vaccine

AstriVax Therapeutics is fast-tracking the validation and proof-of-concept for its proprietary Launch-IT technology by testing AVX70481, a Yellow Fever/RabG-based viral vector designed for the prevention of yellow fever and rabies. Using biomarker data (Correlates of Protection), the company aims to further confirm the platform’s efficacy, scalability, and potential for broader applications.

Development status: Ongoing Phase I clinical study (SAFYR) testing the safety and Immune response of AVX70481.